Calcitonin intranasal - Novartis

Drug Profile

Calcitonin intranasal - Novartis

Alternative Names: Miacalcin Nasal Spray; Miacalcin® intranasal; Salcatonin intranasal - Novartis

Latest Information Update: 01 Aug 2012

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novogyne Pharmaceuticals
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 20 Jul 2012 The European Medicines Agency recommended that intranasal calcitonin-containing medicines should not be used for osteoporosis. Due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
  • 03 Dec 2002 The CPMP has recommended approval of intranasal calcitonin for treatment of established post-menopausal osteoporosis throughout the European Union
  • 31 Dec 2001 Launched for Postmenopausal osteoporosis treatment in Austria (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top